BCLI
BRAINSTORM CELL THERAPEUTICS INC.Company Information
- Company Name
- BRAINSTORM CELL THERAPEUTICS INC.
- CIK
- CIK0001137883
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BCLI: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- BCLI
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-10-01
- Last sale
- 2024-07-19
- Shares purchased (TTM)
- 383,208
- Shares sold (TTM)
- 63,000
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 2,164
- Shares outstanding
- 11,008,047
- Ownership
- 0.02%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 6.06%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 3 | 1 | 1 | 1 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Nontrade Receivables Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Assets Current | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 4 | 1 | 2 | 2 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Other Assets Noncurrent | - | - | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 4 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets Noncurrent | 0 | 1 | 1 | - | - | - | 1 | - | - | - | - | - | ||||||
| Assets | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 6 | 3 | 4 | 6 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 7 | 7 | 6 | 6 | 7 | 6 | 5 | 5 | 5 | 5 | 4 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Short Term Borrowings | 1 | 1 | 1 | 0 | 0 | 1 | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Employee Related Liabilities Current | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Liabilities Current | 12 | 12 | 11 | 9 | 9 | 11 | 9 | 7 | 8 | 7 | 8 | 6 | ||||||
| Liabilities | 12 | 12 | 11 | 9 | 9 | 11 | 10 | 8 | 9 | 9 | 9 | 8 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | ||||||
| Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent | - | - | 0 | 0 | 0 | - | 0 | 1 | 1 | 2 | 1 | 0 | ||||||
| Liabilities Noncurrent | - | - | - | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | ||||||
| Warrants And Rights Outstanding | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 231 | 228 | 227 | 227 | 226 | 222 | 219 | 218 | 218 | 213 | 210 | 207 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -243 | -239 | -237 | -235 | - | -230 | -227 | -224 | -221 | -218 | -215 | -209 | ||||||
| Stockholders Equity | -12 | -11 | -10 | -8 | -6 | -7 | -8 | -6 | -4 | -6 | -5 | -3 | ||||||
| Liabilities And Stockholders Equity | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 6 | 3 | 4 | 6 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 100 | 250 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 11 | 11 | 11 | 11 | 10 | 8 | 6 | 5 | 5 | 5 | 4 | 3 | ||||||
| Shares Outstanding | 11 | 11 | 11 | 11 | 10 | 8 | 6 | 5 | 5 | 5 | 4 | 3 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBRAINSTORM CELL THERAPEUTICS INC. (BCLI) — SEC Financial Statements & Analysis
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is a biological products, (no diagnostic substances) company, incorporated in DE. BRAINSTORM CELL THERAPEUTICS INC. trades on OTC as: BCLI. BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, BRAINSTORM CELL THERAPEUTICS INC. carries a market cap of $11.03M, a P/E ratio of -1.05x, a P/B ratio of -0.95x, an enterprise value of $12.09M, and an EV/EBITDA multiple of -1.24x. On profitability, it posts a Return on Equity (ROE) of 119.20% and a Return on Assets (ROA) of -627.43%. Per share, it reports EPS of $-0.95, diluted EPS of $-0.95, free cash flow per share of $-0.37, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -8.09% year-over-year and EPS growth of -28.20% year-over-year. On the balance sheet, it maintains a current ratio of 0.03x, a quick ratio of 0.01x, working capital of $-12.07M, a debt-to-equity ratio of -1.07x, a debt ratio of 15.72, an interest coverage ratio of -7.91x, free cash flow of $-4.06M (TTM), and net debt of $1.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $11.03M
- P/E TTM
- -1.05x
- EPS TTM
- $-0.95
- P/B TTM
- -0.95x
- ROE TTM
- 119.20%
- ROA TTM
- -627.43%
- Debt To Equity
- -1.07x
- Free Cash Flow TTM
- $-4.06M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BRAINSTORM CELL THERAPEUTICS INC. in?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does BCLI trade on?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) trades on the OTC.
Where is BRAINSTORM CELL THERAPEUTICS INC. incorporated?
BRAINSTORM CELL THERAPEUTICS INC. is incorporated in DE.
When was BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s most recent SEC filing?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is BCLI's market cap?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) has a market capitalization of $11.03M as of 2026-06-30.
What is BCLI's EPS (earnings per share)?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s trailing twelve month EPS is $-0.95 as of 2026-06-30.
What is BCLI's ROE (return on equity)?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s trailing twelve month Return on Equity (ROE) is 119.20% as of 2026-06-30.
What is BCLI's ROA (return on assets)?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s trailing twelve month Return on Assets (ROA) is -627.43% as of 2026-06-30.
What is BCLI's EV/EBITDA?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s trailing twelve month EV/EBITDA is -1.24x as of 2026-06-30.